198 related articles for article (PubMed ID: 33326447)
1. Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence.
Dahl HC; Kanchwala M; Thomas-Jardin SE; Sandhu A; Kanumuri P; Nawas AF; Xing C; Lin C; Frigo DE; Delk NA
PLoS One; 2020; 15(12):e0242970. PubMed ID: 33326447
[TBL] [Abstract][Full Text] [Related]
2. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
3. Identification of an IL-1-induced gene expression pattern in AR
Thomas-Jardin SE; Kanchwala MS; Jacob J; Merchant S; Meade RK; Gahnim NM; Nawas AF; Xing C; Delk NA
Prostate; 2018 Jun; 78(8):595-606. PubMed ID: 29527701
[TBL] [Abstract][Full Text] [Related]
4. IL-1-conferred gene expression pattern in ERα
Nawas AF; Kanchwala M; Thomas-Jardin SE; Dahl H; Daescu K; Bautista M; Anunobi V; Wong A; Meade R; Mistry R; Ghatwai N; Bayerl F; Xing C; Delk NA
BMC Cancer; 2020 Jan; 20(1):46. PubMed ID: 31959131
[TBL] [Abstract][Full Text] [Related]
5. Chronic IL-1 Exposed AR
Thomas-Jardin SE; Kanchwala MS; Dahl H; Liu V; Ahuja R; Soundharrajan R; Roos N; Diep S; Sandhu A; Xing C; Delk NA
J Cell Signal; 2021 Dec; 2(4):248-260. PubMed ID: 34988553
[TBL] [Abstract][Full Text] [Related]
6. IL-1β induces p62/SQSTM1 and represses androgen receptor expression in prostate cancer cells.
Chang MA; Patel V; Gwede M; Morgado M; Tomasevich K; Fong EL; Farach-Carson MC; Delk NA
J Cell Biochem; 2014 Dec; 115(12):2188-97. PubMed ID: 25103771
[TBL] [Abstract][Full Text] [Related]
7. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.
Puhr M; Hoefer J; Eigentler A; Dietrich D; van Leenders G; Uhl B; Hoogland M; Handle F; Schlick B; Neuwirt H; Sailer V; Kristiansen G; Klocker H; Culig Z
Oncogene; 2016 May; 35(18):2322-32. PubMed ID: 26257066
[TBL] [Abstract][Full Text] [Related]
8. Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation.
Debelec-Butuner B; Alapinar C; Varisli L; Erbaykent-Tepedelen B; Hamid SM; Gonen-Korkmaz C; Korkmaz KS
Mol Carcinog; 2014 Feb; 53(2):85-97. PubMed ID: 22911881
[TBL] [Abstract][Full Text] [Related]
9. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha.
Ko S; Shi L; Kim S; Song CS; Chatterjee B
Mol Endocrinol; 2008 Feb; 22(2):273-86. PubMed ID: 17975021
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
[TBL] [Abstract][Full Text] [Related]
12. Stromal TGF-β signaling induces AR activation in prostate cancer.
Yang F; Chen Y; Shen T; Guo D; Dakhova O; Ittmann MM; Creighton CJ; Zhang Y; Dang TD; Rowley DR
Oncotarget; 2014 Nov; 5(21):10854-69. PubMed ID: 25333263
[TBL] [Abstract][Full Text] [Related]
13. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
14. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
15. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
16.
Özgür E; Celik AI; Darendeliler E; Gezer U
Anticancer Res; 2017 Jul; 37(7):3631-3637. PubMed ID: 28668854
[TBL] [Abstract][Full Text] [Related]
17. The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma.
Paximadis P; Najy AJ; Snyder M; Kim HR
Prostate; 2016 May; 76(6):534-42. PubMed ID: 26732854
[TBL] [Abstract][Full Text] [Related]
18. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
Hoefer J; Akbor M; Handle F; Ofer P; Puhr M; Parson W; Culig Z; Klocker H; Heidegger I
Oncotarget; 2016 Sep; 7(37):59781-59794. PubMed ID: 27486973
[TBL] [Abstract][Full Text] [Related]
19. Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy.
Geng H; Xue C; Mendonca J; Sun XX; Liu Q; Reardon PN; Chen Y; Qian K; Hua V; Chen A; Pan F; Yuan J; Dang S; Beer TM; Dai MS; Kachhap SK; Qian DZ
Nat Commun; 2018 Nov; 9(1):4972. PubMed ID: 30478344
[TBL] [Abstract][Full Text] [Related]
20. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]